Respiratory syncytial virus

Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use

Summary of Kuwait’s updated RSV prevention policy

Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis

Nirsevimab FAQs

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

An easy guide to use Nirsevimab